Sala de prensa
Notas de prensa
Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer
Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from…
Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination
Preclinical data support the potential of ONA-XR plus estrogen receptor degraders in endocrine resistant disease models Context to initiate Phase…
Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO®(selinexor) for the Treatment of Patients with…
– Based on Results from Phase 3 BOSTON Study, Marketing Authorisation Expands Multiple Myeloma Indication – – Approval Follows Positive…
Los mejores del deporte se reúnen para la gran final del XXVI Fair Play Menarini International Award
Los mejores del deporte se reúnen bajo las estrellas para la gran final del XXVI Fair Play Menarini International Award…
NewAmsterdam Pharma y Grupo Menarini firman un acuerdo de licencia para comercializar obicetrapib en Europa
Este nuevo acuerdo combina el programa clínico líder de NewAmsterdam, obicetrapib, con la profunda experiencia regional y en enfermedades cardiovasculares…
Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at…
Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an investigational oral selective…
